<DOC>
	<DOC>NCT02990481</DOC>
	<brief_summary>1. To determine the maximum tolerated dose (MTD) and the dose limiting toxicities (DLTs) of TRK-950 as single agent 2. To establish the dose of TRK-950 recommended for future phase 2 studies</brief_summary>
	<brief_title>A Study of TRK-950 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This study is a first-in-human study of TRK-950 in patients with advanced solid tumors and is primarily designed to determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of TRK-950 administered via intravenous (IV) infusion once weekly for 3 weeks every 28 days.</detailed_description>
	<criteria>Patients with histologically confirmed locally advanced or metastatic solid carcinomas Tumor progression after receiving standard/approved chemotherapy or where there is no approved therapy or not amendable to a curative treatment Measurable disease per RECIST 1.1 (primary or metastases) New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy Pregnant or nursing women Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entry Unwillingness or inability to comply with procedures required in this protocol Known active infection with HIV, hepatitis B, hepatitis C Symptomatic brain metastases Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor Patients who are currently receiving any other investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>